Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Despite the chronic nature of fibrotic conditions, widespread impact on various organs, and substantial disease burden, there is currently no curative treatment for these conditions. The strategic partnership will combine Variant Bio’s genomic discovery capabilities and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!